These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7474556)

  • 21. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative antioxidant effects of beta-adrenoceptor blockers, calcium antagonists and U-74500A against iron-dependent lipid peroxidation in murine ventricular microsomal membranes.
    Reddy DS; Singh M; Chopra K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):559-67. PubMed ID: 9010829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.
    Fitscha P; Meisner W; Tiso B
    Eur J Clin Pharmacol; 1988; 34(4):359-62. PubMed ID: 2900143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bopindolol and its metabolite 18-502 attenuate regional myocardial acidosis during partial occlusion of the coronary artery in dogs.
    Abiko Y; Gotoh H; Yokoyama T; Abiko T; Hashizume H; Akiyama K
    Arch Int Pharmacodyn Ther; 1994; 327(1):40-55. PubMed ID: 7944827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-adrenoceptor blocking effects of two bopindolol metabolites in isolated guinea-pig atria.
    Brasch H; Dominiak P
    Arzneimittelforschung; 1992 Feb; 42(2):97-100. PubMed ID: 1351728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.
    Brodde OE; Wang XL; O'Hara N; Daul A; Schiess W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S70-3. PubMed ID: 2439825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of bopindolol on renin secretion and renal excretory function in rats.
    Proakis AG; Barrett RJ; Anderson LA; Wright KF; Taylor DR
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):862-9. PubMed ID: 2484080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.
    Dayer P; Mérier G; Perrenoud JJ; Marmy A; Leemann T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S20-4. PubMed ID: 2439813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of affinities of propranolol and bopindolol to membranes from COS-7 cell transiently transfected with beta-1- and beta-2-adrenoceptors using a radioligand-binding assay method.
    Nakamura T; Suzuki A; Ohnuki T; Hattori K; Watanabe K; Kurose H; Nagao T; Nagatomo T
    Pharmacology; 2000 Jul; 61(1):6-10. PubMed ID: 10895074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: a novel mechanism of action of beta-blockers.
    Liu XK; Engelman RM; Agrawal HR; Das DK
    J Mol Cell Cardiol; 1991 Oct; 23(10):1091-100. PubMed ID: 1684206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bopindolol, a new long-acting beta-adrenoceptor antagonist--a randomized comparison against propranolol in hypertensive patients.
    Kirch W; Axthelm T
    Int J Clin Pharmacol Res; 1983; 3(2):89-93. PubMed ID: 6148312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on relationships between chemical structure and beta-blocking potency of bopindolol and its two metabolites.
    Nagatomo T; Ishiguro M; Ohnuki T; Hattori K; Hosohata Y; Takatsu N; Katayama H; Watanabe K
    Life Sci; 1998; 62(17-18):1597-600. PubMed ID: 9585142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol.
    De Blasi A; Fratelli M; Marasco O
    Circ Res; 1988 Aug; 63(2):273-8. PubMed ID: 2899461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of lipid peroxidation by pindolol.
    Miura T; Muraoka S; Fujimoto Y
    Pharmacol Toxicol; 1999 Mar; 84(3):130-4. PubMed ID: 10193674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of cyanopindolol analogues active at the beta 3-adrenoceptor in rat ileum.
    Hoey AJ; Jackson CM; Pegg GG; Sillence MN
    Br J Pharmacol; 1996 Oct; 119(3):564-8. PubMed ID: 8894179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-1 and beta-adrenergic receptor blocking potencies of bopindolol and its two metabolites (18-502 and 20-785) as assessed by radioligand binding assay methods.
    Hosohata Y; Sasaki K; Suzuki M; Karakisawa Y; Maruyama K; Tsuchihashi H; Nagatomo T
    Gen Pharmacol; 1995 Jul; 26(4):743-7. PubMed ID: 7635249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs.
    Melena J; Osborne NN
    Graefes Arch Clin Exp Ophthalmol; 2003 Oct; 241(10):827-33. PubMed ID: 12898280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological characteristics of the long-acting beta-blocker "bopindolol"].
    Nagatomo T; Hosohata Y; Ohnuki T; Suzuki J
    Nihon Yakurigaku Zasshi; 1997 Jan; 109(1):1-12. PubMed ID: 9067994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.